title: Sorafenib in advanced, heavily pretreated patients with soft tissue sarcomas.
abstract: Therapeutic options for patients with advanced pretreated soft tissue sarcomas are limited. However, in this setting, sorafenib has shown promising results. We reviewed the data of 33 patients with soft tissue sarcoma treated with sorafenib within a named patient program in Austria. Twelve physicians from eight different hospitals provided records for the analysis of data. Among the 33 patients, the predominant histological subtype of sarcoma was leiomyosarcoma (n=18, 55%). Other subtypes were represented by only one or two cases. Fifteen patients presented with metastases at the time of diagnosis. Another 17 patients developed metastases later in the course of the disease (data on one patient are missing). Most of the 33 patients had undergone resection of the primary (n=29, 88%) and half of the patients had received radiotherapy (n=17, 52%). Chemotherapy for metastatic disease had been administered to 30 patients (91%). The majority had received two or more regimens of chemotherapy (n=25, 76%) before sorafenib treatment. The use of sorafenib resulted in a median time to treatment failure of 92 days in patients with leiomyosarcoma and 45 days in patients with other histological subtypes. One-third of the patients derived benefits from treatment: four patients were documented with partial response and six with stabilized disease. In terms of treatment-related toxicity, skin problems of various degrees and gastrointestinal disturbances were frequently reported. In this retrospective analysis of heavily pretreated patients with advanced soft tissue sarcomas, sorafenib was associated with some antitumor activity and an acceptable toxicity profile.
authors.affiliation: aDepartment of Internal Medicine I, Division of Oncology, Comprehensive Cancer Center, Medical University of Vienna bDepartment of Medicine I and Medical Oncology, Wilhelminenspital cDepartment of Gynecology, Medical University of Vienna, Vienna dDepartment of Internal Medicine, Division of Oncology, Medical University of Graz, Graz eDepartment of Internal Medicine, Medical University of Innsbruck, Innsbruck fDepartment of Haematology and Oncology, Hospital Wels-Grieskirchen, Wels g3rd Medical Department with Haematology, Medical Oncology, Haemostaseology, Rheumatology and Infectious Diseases, Paracelsus Medical University Salzburg, Salzburg hInternal Medicine I, Department of Medical Oncology, Haematology and Gastroenterology, Hospital Barmherzige Schwestern Linz iInternal Medicine I, Elisabethinen Hospital Linz jDepartment of Internal Medicine III, Center for Medical Oncology and Haematology, General Hospital Linz, Linz kDepartment of Internal Medicine, Saint Vincent Hospital Zams, Zams, Austria.
authors.forename: Kira
authors.initials: K
authors.lastname: Brämswig
authors.forename: Ferdinand
authors.initials: F
authors.lastname: Ploner
authors.forename: Alexandra
authors.initials: A
authors.lastname: Martel
authors.forename: Thomas
authors.initials: T
authors.lastname: Bauernhofer
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Hilbe
authors.forename: Thomas
authors.initials: T
authors.lastname: Kühr
authors.forename: Clemens
authors.initials: C
authors.lastname: Leitgeb
authors.forename: Brigitte
authors.initials: B
authors.lastname: Mlineritsch
authors.forename: Andreas
authors.initials: A
authors.lastname: Petzer
authors.forename: Veronika
authors.initials: V
authors.lastname: Seebacher
authors.forename: Herbert
authors.initials: H
authors.lastname: Stöger
authors.forename: Michael
authors.initials: M
authors.lastname: Girschikofsky
authors.forename: Gerhard
authors.initials: G
authors.lastname: Hochreiner
authors.forename: Sigrun
authors.initials: S
authors.lastname: Ressler
authors.forename: Franz
authors.initials: F
authors.lastname: Romeder
authors.forename: Ewald
authors.initials: E
authors.lastname: Wöll
authors.forename: Thomas
authors.initials: T
authors.lastname: Brodowicz
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007890:Leiomyosarcoma / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009536:Niacinamide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000077157:Sorafenib; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib